A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia.

[1]  R. Lock,et al.  Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in CRLF2-Rearranged Ph-like ALL , 2020, Molecular Cancer Research.

[2]  J. A. MacKay,et al.  Anti-FLT3 nanoparticles for acute myeloid leukemia: Preclinical pharmacology and pharmacokinetics. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[3]  C. Pui,et al.  Immunotherapy in pediatric acute lymphoblastic leukemia , 2019, Cancer and Metastasis Reviews.

[4]  Yongping Song,et al.  Recent advances on blinatumomab for acute lymphoblastic leukemia , 2019, Experimental Hematology & Oncology.

[5]  Louise N. Winteringham,et al.  Expression Levels of Therapeutic Targets as Indicators of Sensitivity to Targeted Therapeutics , 2019, Molecular Cancer Therapeutics.

[6]  P. Houghton,et al.  Preclinical activity of the antibody‐drug conjugate denintuzumab mafodotin (SGN‐CD19A) against pediatric acute lymphoblastic leukemia xenografts , 2019, Pediatric blood & cancer.

[7]  C. Mackall,et al.  Tumor Antigen Escape from CAR T-cell Therapy. , 2018, Cancer discovery.

[8]  J. Otlewski,et al.  High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1 , 2018, International journal of molecular sciences.

[9]  Benjamin T. Porebski,et al.  Germinal center antibody mutation trajectories are determined by rapid self/foreign discrimination , 2018, Science.

[10]  M. Loh,et al.  Philadelphia chromosome-like acute lymphoblastic leukemia. , 2017, Blood.

[11]  T. Valerius,et al.  Antibody Isotypes for Tumor Immunotherapy , 2017, Transfusion Medicine and Hemotherapy.

[12]  C. Pui,et al.  Philadelphia Chromosome–like Acute Lymphoblastic Leukemia , 2017, Clinical lymphoma, myeloma & leukemia.

[13]  S. Lipshultz,et al.  Chemotherapy-induced cardiotoxicity in children , 2017, Expert opinion on drug metabolism & toxicology.

[14]  V. Anderson,et al.  The relationship between cognitive and neuroimaging outcomes in children treated for acute lymphoblastic leukemia with chemotherapy only: A systematic review , 2017, Pediatric blood & cancer.

[15]  Pratyoosh Shukla,et al.  Microbial platform technology for recombinant antibody fragment production: A review , 2017, Critical reviews in microbiology.

[16]  M. Maus,et al.  Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies , 2016, Computational and structural biotechnology journal.

[17]  O. Abdel-Rahman.  Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. , 2016, Critical reviews in oncology/hematology.

[18]  D. Auguste,et al.  Cancer targeted therapeutics: From molecules to drug delivery vehicles. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[19]  J. Pourahmad,et al.  Isolated Human Peripheral Blood Mononuclear Cell (PBMC), a Cost Effective Tool for Predicting Immunosuppressive Effects of Drugs and Xenobiotics , 2015, Iranian journal of pharmaceutical research : IJPR.

[20]  Tamer Refaat,et al.  Cancer active targeting by nanoparticles: a comprehensive review of literature , 2015, Journal of Cancer Research and Clinical Oncology.

[21]  D. Schatz,et al.  Mapping and Quantitation of the Interaction between the Recombination Activating Gene Proteins RAG1 and RAG2*♦ , 2015, The Journal of Biological Chemistry.

[22]  Jeffrey E. Lee,et al.  Measuring Protein‐Protein and Protein‐Nucleic Acid Interactions by Biolayer Interferometry , 2015, Current protocols in protein science.

[23]  Christof Fellmann,et al.  An optimized microRNA backbone for effective single-copy RNAi. , 2013, Cell reports.

[24]  R. Nadeau,et al.  Anti‐CRLF2 Antibody‐Armored Biodegradable Nanoparticles for Childhood B‐ALL , 2013, Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems.

[25]  Matthew J. Brauer,et al.  Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma , 2013, Journal of Translational Medicine.

[26]  W. Luttmann,et al.  Expression analysis and specific blockade of the receptor for human thymic stromal lymphopoietin (TSLP) by novel antibodies to the human TSLPRα receptor chain. , 2013, Cytokine.

[27]  Aik Choon Tan,et al.  Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.

[28]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[29]  Akhilesh Pandey,et al.  TSLP Signaling Network Revealed by SILAC-Based Phosphoproteomics* , 2012, Molecular & Cellular Proteomics.

[30]  T. Wilson,et al.  Resolution and optical sectioning in the confocal microscope , 2011, Journal of microscopy.

[31]  J. Paulson,et al.  CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells , 2011, The Journal of Immunology.

[32]  V. Ramakrishnan,et al.  Investigational antibody-drug conjugates for hematological malignancies , 2011, Expert opinion on investigational drugs.

[33]  W. Leonard,et al.  Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7–induced signaling , 2010, Proceedings of the National Academy of Sciences.

[34]  J. Downing,et al.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. , 2010, Blood.

[35]  Ww Cheng,et al.  The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment , 2010, Expert opinion on drug delivery.

[36]  A. Mackensen,et al.  Novel conjugates of single‐chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells , 2010, British journal of haematology.

[37]  L. Hennighausen,et al.  Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia , 2010, EMBO molecular medicine.

[38]  Sebastian Krause,et al.  Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function , 2010, Biological chemistry.

[39]  A. Nelson.  Antibody fragments , 2010, mAbs.

[40]  Takashi Akasaka,et al.  Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. , 2009, Blood.

[41]  I. Pastan,et al.  Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. , 2008, Cancer research.

[42]  A. Ullrich,et al.  Paul Ehrlich's magic bullet concept: 100 years of progress , 2008, Nature Reviews Cancer.

[43]  Michael M. Schmidt,et al.  Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability , 2008, Cancer Immunology, Immunotherapy.

[44]  A. Ebens,et al.  Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. , 2006, Blood.

[45]  O. Trubiani,et al.  Sphingolipid Microdomains Mediate CD38 Internalization: Topography of the Endocytosis , 2004, International journal of immunopathology and pharmacology.

[46]  R. Lock,et al.  Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. , 2004, Blood.

[47]  Theresa M Allen,et al.  Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. , 2002, Cancer research.

[48]  J. Doré,et al.  Internalization-Dependent and -Independent Requirements for Transforming Growth Factor β Receptor Signaling via the Smad Pathway , 2002, Molecular and Cellular Biology.

[49]  R. Lock,et al.  The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. , 2002, Blood.

[50]  R. de Waal Malefyt,et al.  Human Thymic Stromal Lymphopoietin Preferentially Stimulates Myeloid Cells1 , 2001, The Journal of Immunology.

[51]  G. Adams,et al.  High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.

[52]  T M Allen,et al.  In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. , 1998, Cancer research.

[53]  P. Bjorkman,et al.  Crystal Structure of the Hemochromatosis Protein HFE and Characterization of Its Interaction with Transferrin Receptor , 1998, Cell.

[54]  P. Sorensen,et al.  Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. , 2015, Blood.

[55]  T M Allen,et al.  Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. , 2007, Biochimica et biophysica acta.

[56]  B. Kroesen,et al.  Simultaneous inhibition of EGFR signaling and enhanced activation of TRAIL-R-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. , 2022 .